PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 2297765-9 1990 Calmodulin prepared from resistant cells were equally sensitive to inhibition by dequalinium and trifluoperazine. Dequalinium 81-92 calmodulin 2 Mus musculus 0-10 3329523-6 1987 Dequalinium and rhodamine-123, drugs selectively accumulated in malignant cells, were found to be potent calmodulin antagonists, and inhibited the growth of C6 astrocytoma cells. Dequalinium 0-11 calmodulin 1 Homo sapiens 105-115 33496065-6 2021 Dequalinium chloride is an inhibitor of XIAP and can also act as a mitochondrial targeting agent, which gives it an interesting perspective regarding recent advances in the treatment of malignant glioma. Dequalinium 0-20 X-linked inhibitor of apoptosis Homo sapiens 40-44 33964033-13 2021 Fluvastatin reduced IL8, IL6, CCL21, AQP9 (p<0.001) and MMP9 (p<0.05) in the ex-vivo pulpitis model, while dequalinium chloride reduced AQP9 (p<0.001) but had no significant effect on the other biomarkers. Dequalinium 107-127 aquaporin 9 Homo sapiens 136-140 33467773-2 2021 We utilized in silico prediction of biological activity spectra for substances (PASS) analysis to estimate the potential biological activity profile of deethylated ethoxyquin (DEQ) and hypothesized that DEQ exhibits antioxidant and anti-inflammatory effects in a rat model of carbon tetrachloride (CCl4)-induced ALI. Dequalinium 176-179 C-C motif chemokine ligand 4 Rattus norvegicus 298-302 33467773-2 2021 We utilized in silico prediction of biological activity spectra for substances (PASS) analysis to estimate the potential biological activity profile of deethylated ethoxyquin (DEQ) and hypothesized that DEQ exhibits antioxidant and anti-inflammatory effects in a rat model of carbon tetrachloride (CCl4)-induced ALI. Dequalinium 203-206 C-C motif chemokine ligand 4 Rattus norvegicus 298-302 33467773-4 2021 Treatment with DEQ reduced CCl4-induced elevation of gene expression, and the activity of antioxidant enzymes (AEs), as well as the expression of transcription factors Nfe2l2 and Nfkb2. Dequalinium 15-18 C-C motif chemokine ligand 4 Rattus norvegicus 27-31 33467773-4 2021 Treatment with DEQ reduced CCl4-induced elevation of gene expression, and the activity of antioxidant enzymes (AEs), as well as the expression of transcription factors Nfe2l2 and Nfkb2. Dequalinium 15-18 NFE2 like bZIP transcription factor 2 Rattus norvegicus 168-174 33467773-4 2021 Treatment with DEQ reduced CCl4-induced elevation of gene expression, and the activity of antioxidant enzymes (AEs), as well as the expression of transcription factors Nfe2l2 and Nfkb2. Dequalinium 15-18 nuclear factor kappa B subunit 2 Rattus norvegicus 179-184 33467773-5 2021 Furthermore, DEQ treatment inhibited apoptosis, downregulated gene expression of pro-inflammatory cytokines (Tnf and Il6), cyclooxygenase 2 (Ptgs2), decreased glutathione (GSH) level and myeloperoxidase (MPO) activity in rats with ALI. Dequalinium 13-16 tumor necrosis factor Rattus norvegicus 109-112 33467773-5 2021 Furthermore, DEQ treatment inhibited apoptosis, downregulated gene expression of pro-inflammatory cytokines (Tnf and Il6), cyclooxygenase 2 (Ptgs2), decreased glutathione (GSH) level and myeloperoxidase (MPO) activity in rats with ALI. Dequalinium 13-16 interleukin 6 Rattus norvegicus 117-120 33467773-5 2021 Furthermore, DEQ treatment inhibited apoptosis, downregulated gene expression of pro-inflammatory cytokines (Tnf and Il6), cyclooxygenase 2 (Ptgs2), decreased glutathione (GSH) level and myeloperoxidase (MPO) activity in rats with ALI. Dequalinium 13-16 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 123-139 33467773-5 2021 Furthermore, DEQ treatment inhibited apoptosis, downregulated gene expression of pro-inflammatory cytokines (Tnf and Il6), cyclooxygenase 2 (Ptgs2), decreased glutathione (GSH) level and myeloperoxidase (MPO) activity in rats with ALI. Dequalinium 13-16 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 141-146 33467773-5 2021 Furthermore, DEQ treatment inhibited apoptosis, downregulated gene expression of pro-inflammatory cytokines (Tnf and Il6), cyclooxygenase 2 (Ptgs2), decreased glutathione (GSH) level and myeloperoxidase (MPO) activity in rats with ALI. Dequalinium 13-16 myeloperoxidase Rattus norvegicus 187-202 33467773-5 2021 Furthermore, DEQ treatment inhibited apoptosis, downregulated gene expression of pro-inflammatory cytokines (Tnf and Il6), cyclooxygenase 2 (Ptgs2), decreased glutathione (GSH) level and myeloperoxidase (MPO) activity in rats with ALI. Dequalinium 13-16 myeloperoxidase Rattus norvegicus 204-207 33467773-6 2021 Notably, DEQ treatment led to an inhibition of CCl4-induced NLRP3-inflammasome activation which was indicated by the reduced protein expression of IL-1beta, caspase-1, and NLRP3 in the liver. Dequalinium 9-12 C-C motif chemokine ligand 4 Rattus norvegicus 47-51 33467773-6 2021 Notably, DEQ treatment led to an inhibition of CCl4-induced NLRP3-inflammasome activation which was indicated by the reduced protein expression of IL-1beta, caspase-1, and NLRP3 in the liver. Dequalinium 9-12 NLR family, pyrin domain containing 3 Rattus norvegicus 60-65 33467773-6 2021 Notably, DEQ treatment led to an inhibition of CCl4-induced NLRP3-inflammasome activation which was indicated by the reduced protein expression of IL-1beta, caspase-1, and NLRP3 in the liver. Dequalinium 9-12 interleukin 1 alpha Rattus norvegicus 147-155 33467773-6 2021 Notably, DEQ treatment led to an inhibition of CCl4-induced NLRP3-inflammasome activation which was indicated by the reduced protein expression of IL-1beta, caspase-1, and NLRP3 in the liver. Dequalinium 9-12 caspase 1 Rattus norvegicus 157-166 33467773-6 2021 Notably, DEQ treatment led to an inhibition of CCl4-induced NLRP3-inflammasome activation which was indicated by the reduced protein expression of IL-1beta, caspase-1, and NLRP3 in the liver. Dequalinium 9-12 NLR family, pyrin domain containing 3 Rattus norvegicus 172-177 33467773-7 2021 Our data suggest that DEQ has a hepatoprotective effect mediated by redox-homeostasis regulation, NLRP3 inflammasome, and apoptosis inhibition, which makes that compound a promising candidate for future clinical studies. Dequalinium 22-25 NLR family, pyrin domain containing 3 Rattus norvegicus 98-103 33428329-7 2021 The compounds (exemplified by dequalinium and dequalinium-inspired analogues) prevent the conformational changes of Env from the prefusion species to the intermediate states required for membrane fusion. Dequalinium 30-41 endogenous retrovirus group K member 20 Homo sapiens 116-119 33428329-7 2021 The compounds (exemplified by dequalinium and dequalinium-inspired analogues) prevent the conformational changes of Env from the prefusion species to the intermediate states required for membrane fusion. Dequalinium 46-57 endogenous retrovirus group K member 20 Homo sapiens 116-119 31919495-10 2020 Instead, we detected drugs, such as dequalinium chloride, which exacerbated the phenotype, and therefore, are potentially harmful to s-adRP patients since they may accelerate the progression of the disease. Dequalinium 36-56 perilipin 2 Homo sapiens 135-139 33166843-3 2020 RACK1-PKC-NF-kappaB signalling axis was suggested as a potential therapeutic target for PRRS control, therefore we tested the inhibitory effect of PKC inhibitor dequalinium chloride (DECA) on the PRRSV infection in vitro. Dequalinium 161-181 receptor for activated C kinase 1 Homo sapiens 0-5 32825082-6 2020 Based on the computational results, six promising molecules were selected and experimentally tested and four of them revealed interesting affinity data; in particular, dequalinium showed a very impressive allosteric modulation for hM2. Dequalinium 168-179 cholinergic receptor muscarinic 2 Homo sapiens 231-234 25237136-6 2014 We tested whether one promising candidate, Food and Drug Administration (FDA)-approved dequalinium chloride (DECA), could restore proper peroxisomal trafficking of AGT(P11LG170R). Dequalinium 87-107 alanine--glyoxylate and serine--pyruvate aminotransferase Homo sapiens 164-167 30293817-8 2018 FINDINGS: Our data showed that dequalinium chloride and clofoctol we screened inhibit S phase progression, accumulation in G2/M phase, and Cdc7 kinase activity. Dequalinium 31-51 cell division cycle 7 Homo sapiens 139-143 25322811-4 2015 We found that the proteasome inhibitor MG-132 specifically induces in NB4 cells an Nrf2-mediated antioxidant response which counteracts mitochondria-dependent apoptosis induced by the lipophilic cation dequalinium. Dequalinium 202-213 NFE2 like bZIP transcription factor 2 Homo sapiens 83-87 24811390-0 2014 Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. Dequalinium 0-11 zinc fingers and homeoboxes 2 Homo sapiens 82-85 24811390-0 2014 Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. Dequalinium 0-11 mitogen-activated protein kinase kinase 7 Homo sapiens 86-89 24811390-0 2014 Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. Dequalinium 0-11 mitogen-activated protein kinase 1 Homo sapiens 90-93 24811390-0 2014 Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. Dequalinium 0-11 AKT serine/threonine kinase 1 Homo sapiens 103-106 24952669-5 2014 A XIAP inhibitor (Dequalinium chloride, DQA) was identified in an in silico screening searching for small molecules that induce similar gene expression regulation. Dequalinium 18-38 X-linked inhibitor of apoptosis Homo sapiens 2-6 21340509-0 2011 Characterization of dequalinium as a XIAP antagonist that targets the BIR2 domain. Dequalinium 20-31 X-linked inhibitor of apoptosis Homo sapiens 37-41 22875343-0 2012 Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562. Dequalinium 57-68 zinc fingers and homeoboxes 2 Homo sapiens 0-3 22875343-0 2012 Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562. Dequalinium 57-68 mitogen-activated protein kinase kinase 7 Homo sapiens 4-7 22875343-0 2012 Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562. Dequalinium 57-68 mitogen-activated protein kinase 1 Homo sapiens 8-11 19007333-4 2009 The fibrillation-state-specific interaction of JC-1 allowed us to perform real-time analyses of the alpha-synuclein fibrillation in the presence of iron as a fibrillation inducer, rifampicin as a fibrillation inhibitor, baicalein as a defibrillation agent and dequalinium as a protofibril inducer. Dequalinium 260-271 synuclein alpha Homo sapiens 100-115 18616285-6 2008 Structures of QacR(E57Q) and QacR(E58Q) bound to dequalinium indicated that E57 and E58 are redundant for charge neutralization. Dequalinium 49-60 QacR Staphylococcus aureus 14-18 18616285-6 2008 Structures of QacR(E57Q) and QacR(E58Q) bound to dequalinium indicated that E57 and E58 are redundant for charge neutralization. Dequalinium 49-60 QacR Staphylococcus aureus 29-33 18295794-1 2008 EmrE is a Small Multidrug Resistance transporter (SMR) family member that mediates counter transport of protons and hydrophobic cationic drugs such as tetraphenylphosphonium (TPP+), ethidium, propidium and dequalinium. Dequalinium 206-217 single-pass membrane protein with aspartate rich tail 1 Homo sapiens 0-4 18048454-5 2008 Concentration-response relationships for apamin and dequalinium had IC(50) values of 0.5 nm and 1.8 microm, respectively, consistent with data previously reported for SK3 channels in excitable cells and hepatocytes. Dequalinium 52-63 potassium calcium-activated channel subfamily N member 3 Homo sapiens 167-170 18295794-4 2008 Here, using electron cryomicroscopy of EmrE two-dimensional crystals we have determined projection structures of EmrE bound to three structurally different planar drugs, ethidium, propidium and dequalinium. Dequalinium 194-205 single-pass membrane protein with aspartate rich tail 1 Homo sapiens 39-43 18295794-4 2008 Here, using electron cryomicroscopy of EmrE two-dimensional crystals we have determined projection structures of EmrE bound to three structurally different planar drugs, ethidium, propidium and dequalinium. Dequalinium 194-205 single-pass membrane protein with aspartate rich tail 1 Homo sapiens 113-117 15928936-1 2005 Dequalinium has recently been reported to block CNGA1 and CNGA2 channels expressed in Xenopus laevis. Dequalinium 0-11 cyclic nucleotide gated channel alpha 1 L homeolog Xenopus laevis 48-53 16330551-0 2006 Dequalinium-induced protofibril formation of alpha-synuclein. Dequalinium 0-11 synuclein alpha Homo sapiens 45-60 16330551-3 2006 In order to develop a controlling strategy toward the amyloid formation, 1,1"-(1,10-decanediyl)-bis-[4-a-mino-2-methylquinolinium] (dequalinium), was selected and examined in terms of its specific molecular interaction with alpha-synuclein. Dequalinium 73-130 synuclein alpha Homo sapiens 224-239 16330551-3 2006 In order to develop a controlling strategy toward the amyloid formation, 1,1"-(1,10-decanediyl)-bis-[4-a-mino-2-methylquinolinium] (dequalinium), was selected and examined in terms of its specific molecular interaction with alpha-synuclein. Dequalinium 132-143 synuclein alpha Homo sapiens 224-239 16330551-9 2006 In addition, dequalinium treatment of the alpha-synuclein-overexpressing cells exerted a significant cell death. Dequalinium 13-24 synuclein alpha Homo sapiens 42-57 16330551-10 2006 Therefore, it is pertinent to consider that dequalinium could be used as a molecular probe to assess toxic mechanisms related to the amyloid formation of alpha-synuclein. Dequalinium 44-55 synuclein alpha Homo sapiens 154-169 15928936-1 2005 Dequalinium has recently been reported to block CNGA1 and CNGA2 channels expressed in Xenopus laevis. Dequalinium 0-11 cyclic nucleotide gated channel subunit alpha 2 Rattus norvegicus 58-63 15928936-2 2005 Using the inside-out configuration of the patch-clamp technique, we examined the effects of dequalinium on rat olfactory CNGA2 channels expressed in human embryonic kidney (HEK293) cells and studied aspects of its molecular mechanism of action. Dequalinium 92-103 cyclic nucleotide gated channel subunit alpha 2 Rattus norvegicus 121-126 15928936-3 2005 We found that cytoplasmic dequalinium blocked wild-type (WT) CNGA2 channels in a voltage-dependent manner with an IC(50) of approximately 1.3 muM at a V(m) of + 60 mV, and an effective fractional charge, zdelta, of +0.8 (z=2, delta=+0.4), suggesting that cytoplasmic dequalinium interacts with a binding site that is about two fifths of the way along the membrane electric field (from the intracellular side). Dequalinium 26-37 cyclic nucleotide gated channel subunit alpha 2 Rattus norvegicus 61-66 15928936-3 2005 We found that cytoplasmic dequalinium blocked wild-type (WT) CNGA2 channels in a voltage-dependent manner with an IC(50) of approximately 1.3 muM at a V(m) of + 60 mV, and an effective fractional charge, zdelta, of +0.8 (z=2, delta=+0.4), suggesting that cytoplasmic dequalinium interacts with a binding site that is about two fifths of the way along the membrane electric field (from the intracellular side). Dequalinium 267-278 cyclic nucleotide gated channel subunit alpha 2 Rattus norvegicus 61-66 14726520-4 2004 To date, the structure of only one QacR-bivalent cationic drug complex (that of QacR bound to dequalinium) has been determined, and how other longer or shorter bivalent cationic compounds bind is unknown. Dequalinium 94-105 QacR Staphylococcus aureus 35-39 16164036-7 2005 The PKC inhibitor Dequalinium chloride (DECA) remarkably reduced the production of IL-6, NF-kappaB and the activity of PKC induced by the piliated S. typhi. Dequalinium 18-38 proline rich transmembrane protein 2 Homo sapiens 4-7 16164036-7 2005 The PKC inhibitor Dequalinium chloride (DECA) remarkably reduced the production of IL-6, NF-kappaB and the activity of PKC induced by the piliated S. typhi. Dequalinium 18-38 interleukin 6 Homo sapiens 83-87 16164036-7 2005 The PKC inhibitor Dequalinium chloride (DECA) remarkably reduced the production of IL-6, NF-kappaB and the activity of PKC induced by the piliated S. typhi. Dequalinium 18-38 nuclear factor kappa B subunit 1 Homo sapiens 89-98 16164036-7 2005 The PKC inhibitor Dequalinium chloride (DECA) remarkably reduced the production of IL-6, NF-kappaB and the activity of PKC induced by the piliated S. typhi. Dequalinium 18-38 proline rich transmembrane protein 2 Homo sapiens 119-122 14726520-4 2004 To date, the structure of only one QacR-bivalent cationic drug complex (that of QacR bound to dequalinium) has been determined, and how other longer or shorter bivalent cationic compounds bind is unknown. Dequalinium 94-105 QacR Staphylococcus aureus 80-84 14657188-6 2004 Human cultured cell lines transfected with SK2 yielded Ca(2+)-sensitive K+ current that was blocked by dequalinium chloride and apamin, known blockers of SK channels. Dequalinium 103-123 sphingosine kinase 2 Homo sapiens 43-46 14657188-7 2004 Xenopus oocytes injected with SK2 in vitro transcribed RNA, under conditions where only outward K+ currents could be recorded, expressed an outward current that was sensitive to EGTA, dequalinium chloride, and apamin. Dequalinium 184-204 sphingosine kinase 2 Homo sapiens 30-33 14981138-4 2004 We previously noted that dequalinium is a high-affinity blocker of CNGA1 channels from the intracellular side, with little or no state dependence at 0 mV. Dequalinium 25-36 cyclic nucleotide gated channel subunit alpha 1 Homo sapiens 67-72 14981138-5 2004 Here we examined block by dequalinium at a broad range of voltages in both CNGA1 and CNGA2 channels. Dequalinium 26-37 cyclic nucleotide gated channel subunit alpha 1 Homo sapiens 75-80 14981138-5 2004 Here we examined block by dequalinium at a broad range of voltages in both CNGA1 and CNGA2 channels. Dequalinium 26-37 cyclic nucleotide gated channel subunit alpha 2 Homo sapiens 85-90 12508052-0 2003 Dequalinium: a novel, high-affinity blocker of CNGA1 channels. Dequalinium 0-11 cyclic nucleotide gated channel subunit alpha 1 Rattus norvegicus 47-52 12926074-8 2003 Importantly, amiodarone and dequalinium potentiated the growth-inhibitory effects of tamoxifen on human breast (MCF-7, MDA-MB-231) as well as prostate (PC3, MDA-PCA-2B) and colon (Colo320DM, SW1116) cancer cell lines. Dequalinium 28-39 proprotein convertase subtilisin/kexin type 1 Homo sapiens 152-155 12508052-2 2003 Dequalinium is an organic divalent cation which suppresses the rat small conductance Ca(2+)-activated K(+) channel 2 (rSK2) and the activity of protein kinase C. In this study, we have tested the ability of dequalinium to block CNGA1 channels and heteromeric CNGA1+CNGB1 channels. Dequalinium 0-11 potassium calcium-activated channel subfamily N member 2 Rattus norvegicus 118-122 12508052-2 2003 Dequalinium is an organic divalent cation which suppresses the rat small conductance Ca(2+)-activated K(+) channel 2 (rSK2) and the activity of protein kinase C. In this study, we have tested the ability of dequalinium to block CNGA1 channels and heteromeric CNGA1+CNGB1 channels. Dequalinium 0-11 cyclic nucleotide gated channel subunit alpha 1 Rattus norvegicus 228-233 12508052-2 2003 Dequalinium is an organic divalent cation which suppresses the rat small conductance Ca(2+)-activated K(+) channel 2 (rSK2) and the activity of protein kinase C. In this study, we have tested the ability of dequalinium to block CNGA1 channels and heteromeric CNGA1+CNGB1 channels. Dequalinium 0-11 cyclic nucleotide gated channel subunit alpha 1 Rattus norvegicus 259-264 12508052-2 2003 Dequalinium is an organic divalent cation which suppresses the rat small conductance Ca(2+)-activated K(+) channel 2 (rSK2) and the activity of protein kinase C. In this study, we have tested the ability of dequalinium to block CNGA1 channels and heteromeric CNGA1+CNGB1 channels. Dequalinium 0-11 cyclic nucleotide gated channel subunit beta 1 Rattus norvegicus 265-270 12508052-3 2003 When applied to the intracellular side of inside-out excised patches from Xenopus oocytes, dequalinium blocks CNGA1 channels with a K(1/2) approximately 190 nM and CNGA1+CNGB1 channels with a K(1/2) approximately 385 nM, at 0 mV. Dequalinium 91-102 cyclic nucleotide gated channel alpha 1 L homeolog Xenopus laevis 110-115 12508052-3 2003 When applied to the intracellular side of inside-out excised patches from Xenopus oocytes, dequalinium blocks CNGA1 channels with a K(1/2) approximately 190 nM and CNGA1+CNGB1 channels with a K(1/2) approximately 385 nM, at 0 mV. Dequalinium 91-102 cyclic nucleotide gated channel alpha 1 L homeolog Xenopus laevis 164-169 12508052-3 2003 When applied to the intracellular side of inside-out excised patches from Xenopus oocytes, dequalinium blocks CNGA1 channels with a K(1/2) approximately 190 nM and CNGA1+CNGB1 channels with a K(1/2) approximately 385 nM, at 0 mV. Dequalinium 91-102 cyclic nucleotide gated channel subunit beta 1 Rattus norvegicus 170-175 10753478-0 2000 Inhibition of protein kinase C(alpha) by dequalinium analogues: dependence on linker length and geometry. Dequalinium 41-52 protein kinase C alpha Homo sapiens 14-37 10696100-7 2000 The antiseptic compound dequalinium chloride blocked hSK1 and rSK2 with IC(50) values of 444 nM and 162 nM, respectively. Dequalinium 24-44 potassium calcium-activated channel subfamily N member 1 Homo sapiens 53-57 10696100-7 2000 The antiseptic compound dequalinium chloride blocked hSK1 and rSK2 with IC(50) values of 444 nM and 162 nM, respectively. Dequalinium 24-44 potassium calcium-activated channel subfamily N member 2 Rattus norvegicus 62-66 9442087-0 1998 Photoinduced inactivation of protein kinase C by dequalinium identifies the RACK-1-binding domain as a recognition site. Dequalinium 49-60 receptor for activated C kinase 1 Homo sapiens 76-82 9442087-1 1998 1,1"-Decamethylenebis-4-aminoquinaldinium diiodide (DECA; dequalinium) is an anti-tumor agent and protein kinase C (PKC) inhibitor whose mechanism of action with PKC is unknown. Dequalinium 58-69 protein kinase C alpha Homo sapiens 116-119 9442087-1 1998 1,1"-Decamethylenebis-4-aminoquinaldinium diiodide (DECA; dequalinium) is an anti-tumor agent and protein kinase C (PKC) inhibitor whose mechanism of action with PKC is unknown. Dequalinium 58-69 protein kinase C alpha Homo sapiens 162-165 8825340-8 1996 The same three compounds inhibited angiotensin II-evoked K+ loss from guinea-pig hepatocytes in the order dequalinium > UCL 1530 > gallamine, with an equi-effective molar ratio for gallamine to UCL 1530 of 5.8, 150 fold less than in sympathetic neurones. Dequalinium 106-117 angiotensinogen Rattus norvegicus 35-49 7851533-1 1995 Various lipophilic cations, such as quinacrine mustard and dequalinium, which are known to inhibit mitochondrial F1-ATPase, strongly inhibited vacuolar H(+)-ATPase purified from bovine adrenal chromaffin granules. Dequalinium 59-70 ATPase H+ transporting V1 subunit B2 Bos taurus 143-163 8100530-1 1993 The bisquaternary compound dequalinium has been tested for its ability to inhibit the loss of K+ which angiotensin II causes in guinea-pig hepatocytes and which occurs through apamin-sensitive Ca(2+)-activated K+ (SKCa) channels. Dequalinium 27-38 angiotensinogen Rattus norvegicus 103-117 8100530-2 1993 Dequalinium blocked angiotensin II-evoked K+ loss with an IC50 of 1.5 +/- 0.1 microM and also inhibited 125I-monoiodoapamin binding with a KI of 1.1 +/- 0.1 microM. Dequalinium 0-11 angiotensinogen Rattus norvegicus 20-34